Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BioLineRx Announces Positive Preliminary Results From The Phase I/II Trial Of BL-1040
BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced positive preliminary results from the ongoing phase I/II clinical trial designed to assess the safety and feasibility of BL-1040, the first injectable device designed to address cardiac remodeling, in 20- 30 patients at several sites in Germany and Belgium. To date, 15 patients were successfully treated with BL-1040 with no complications. Moreover, six months follow up results from the first 5 patients show BL-1040"s efficacy in preventing cardiac remodeling and preserving cardiac function.
generic viagra online
'Taking Up A Dialogue' With The Brain: Letter Decoding From Single-trial Brain Signals
Brain-computer interfaces "translate" what a person is thinking in words or actions. Researchers from Maastricht University in the Netherlands performed functional MRI brain scans on healthy participants, instructing them to "type" by performing mental tasks corresponding to different letters in the English alphabet. Researchers were able to use signals from the participants" brain activation patterns to decode information about the intended letter that a participant was thinking about, and to use this in a conversation with the experimenters without any spoken words. It is hoped that such technology can enable communication with "locked-in" patients or assessment of consciousness in non-responsive patients.
News of the day
Method For Computing Evolutionary Trees Could Revolutionize Evolutionary Biology
Detailed, accurate evolutionary trees that reveal the relatedness of living things can now be determined much faster and for thousands of species with a computing method developed by computer scientists and a biologist at The University of Texas at Austin.
Endocrinology

UK Court Of Appeal Rules In Smith & Nephew's Favour

Smith & Nephew"s Advanced Wound Management division (NYSE:SNN) announced that the UK Court of Appeal has ruled as invalid all claims asserted against Smith and Nephew of the patent EP 0 626 720 that is licensed to Kinetic Concepts, Inc. (NYSE: KCI). As a result, the preliminary injunction against Smith & Nephew"s RENASYS(TM)-F NPWT system has been lifted. The Patents Court had ruled on 1 May, 2009 that 7 out of 10 claims asserted were invalid but that the remaining 3 had been infringed by Smith & Nephews RENASYS-F dressing. This decision was appealed and subsequently won by Smith & Nephew with today"s Court ruling. "This favourable ruling for Smith & Nephew clears a major legal hurdle in the UK allowing us to offer our customers the breadth of NPWT products with proven clinical efficacy," said Robin Carlstein, Senior Vice President of Advanced Wound Devices at Smith & Nephew. "Clearly, we are pleased with the UK Court of Appeal"s findings in this matter and look forward to servicing our customers with our RENASYS(TM)-F NPWT products in a very important market for the company." Smith & Nephew


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009